 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- stroquinan (SP-8203) / Shin Poong Pharma
EFFICACY AND SAFETY OF OTAPLIMASTAT IN PATIENTS WITH ACUTE ISCHEMIC STROKE REQUIRING TPA: A RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 STUDY (Poster area) - Apr 27, 2024 - Abstract #ESOC2024ESOC_1006;
- || Review, Journal: Neuroprotection during Thrombectomy for Acute Ischemic Stroke: A Review of Future Therapies. (Pubmed Central) - Jan 27, 2024
Sedation and blood pressure management in endovascular thrombectomy also play crucial roles in improved stroke outcomes. A hand-in-hand approach with both endovascular therapy and neuroprotection may be the key to targeting disability due to stroke.
- || KUS121 / KDDD, stroquinan (SP-8203) / Shin Poong Pharma, nerinetide (NA 1) / NoNO
Review, Journal: Neuroprotection for Nonarteritic Central Retinal Artery Occlusion: Lessons from Acute Ischemic Stroke. (Pubmed Central) - Jun 7, 2023
Also, neuroprotective research in AIS has been extensive, and newer drugs tested, including Uric acid, Nerinetide, and Otaplimastat, with promising results...Efforts in the field of neuroprotection for NA-CRAO should focus on better imaging to delineate the penumbra after an acute episode of NA-CRAO (using a combination of high-definition optical coherence angiography and electrophysiology). Also, research should explore details of pathophysiologic mechanisms involved in NA-CRAO, allowing for further neuroprotective intervention, and closing the gap between preclinical and clinical neuroprotection.
- | stroquinan (SP-8203) / Shin Poong Pharma
Journal: The Quinazoline Otaplimastat (SP-8203) Reduces the Hemorrhagic Transformation and Mortality Aggravated after Delayed rtPA-Induced Thrombolysis in Cerebral Ischemia. (Pubmed Central) - Apr 9, 2022
In oxygen-glucose-deprived endothelial cells, otaplimastat suppressed the activity rather than protein expression of MMPs by restoring the level of tissue inhibitor of metalloproteinase (TIMP) suppressed in ischemia, and consequently reduced vascular permeation. This paper shows that otaplimastat under clinical trials is a new drug which can inhibit stroke on its own and extend the therapeutic time window of rtPA, especially when administered in combination with rtPA.
- || verapamil / Generic mfg.
Review, Journal: The future of neuroprotection in stroke. (Pubmed Central) - Jun 16, 2021
Some of these compounds yielded promising results which are discussed in this review. Altogether, a deeper knowledge of the mechanisms involved in the ischaemic death process at the neurovascular unit, an improved preselection and evaluation of drugs at the preclinical stage and the testing of putative neuroprotectants in enriched clinical studies of patients receiving reperfusion therapies, might prove more effective than in the past to reverse a dismal situation that has lasted already too long.
- ||| stroquinan (SP-8203) / Shin Poong Pharma
Trial completion: Efficacy and Safety of SP-8203 in Patients With Ischemic Stroke Requiring rtPA (clinicaltrials.gov) - Dec 22, 2020
P2b, N=178, Completed, Sponsor: Shin Poong Pharmaceutical Co. Ltd.
Altogether, a deeper knowledge of the mechanisms involved in the ischaemic death process at the neurovascular unit, an improved preselection and evaluation of drugs at the preclinical stage and the testing of putative neuroprotectants in enriched clinical studies of patients receiving reperfusion therapies, might prove more effective than in the past to reverse a dismal situation that has lasted already too long. Active, not recruiting --> Completed
- || stroquinan (SP-8203) / Shin Poong Pharma
Enrollment closed: Efficacy and Safety of SP-8203 in Patients With Ischemic Stroke Requiring rtPA (clinicaltrials.gov) - Nov 12, 2020
P2b, N=178, Active, not recruiting, Sponsor: Shin Poong Pharmaceutical Co. Ltd.
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- ||| stroquinan (SP-8203) / Shin Poong Pharma
Trial completion: Safety and Efficacy of Two Doses of SP-8203 in Patients With Ischemic Stroke Requiring rtPA (clinicaltrials.gov) - Jul 21, 2020
P2a, N=80, Completed, Sponsor: Shin Poong Pharmaceutical Co. Ltd.
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- ||||| stroquinan (SP-8203) / Shin Poong Pharma
New P2b trial: Efficacy and Safety of SP-8203 in Patients With Ischemic Stroke Requiring rtPA (clinicaltrials.gov) - Jul 21, 2020
P2b, N=178, Recruiting, Sponsor: Shin Poong Pharmaceutical Co. Ltd.
- | stroquinan (SP-8203) / Shin Poong Pharma
Journal: Identification of new fluorophores in coelomic fluid of Eisenia andrei earthworms. (Pubmed Central) - Dec 20, 2019
This compound was earlier indentified in Eisenia andrei as SP-8203...However, our results indicate that this metabolite is also present in E. andrei in significant amounts. The possible origin and function of these new metabolites is discussed.
- ||| stroquinan (SP-8203) / Shin Poong Pharma
Enrollment closed, Trial primary completion date: Safety and Efficacy of Two Doses of SP-8203 in Patients With Ischemic Stroke Requiring rtPA (clinicaltrials.gov) - Aug 11, 2017
P2a, N=80, Active, not recruiting, Sponsor: Shin Poong Pharmaceutical Co. Ltd.
The possible origin and function of these new metabolites is discussed. Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2016 --> Jun 2017
- |||| stroquinan (SP-8203) / Shin Poong Pharma
Enrollment open: Safety and Efficacy of Two Doses of SP-8203 in Patients With Ischemic Stroke Requiring rtPA (clinicaltrials.gov) - Jul 1, 2016
P2a, N=80, Recruiting, Sponsor: Shin Poong Pharmaceutical Co. Ltd.
Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2016 --> Jun 2017 Not yet recruiting --> Recruiting
- ||||| stroquinan (SP-8203) / Shin Poong Pharma
New P2a trial: Safety and Efficacy of Two Doses of SP-8203 in Patients With Ischemic Stroke Requiring rtPA (clinicaltrials.gov) - Jun 1, 2016
P2a, N=80, Not yet recruiting, Sponsor: Shin Poong Pharmaceutical Co. Ltd.
- ||| stroquinan (SP-8203) / Shin Poong Pharma
New P1 trial: Safety, Tolerability and Pharmacokinetics of SP-8203 (clinicaltrials.gov) - Dec 27, 2012
P1, N=80, Not yet recruiting, Sponsor: Shin Poong Pharmaceutical Co. Ltd.